Study Purpose:
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.Study Status:
Recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Observational [Patient Registry]
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Paul Mehta, MD, Centers for Disease Control and Prevention
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
CDC
Paul Mehta, MD / email hidden; JavaScript is required / 770-488-0556
Atlanta, Georgia, 30333 United States
Full Study Summary:
The National ALS Registry's Research Notification System allows person with ALS to participate in clinical trials.
Study Sponsor:
Centers for Disease Control and Prevention
Estimated Enrollment:
17000
Estimated Study Start Date:
10 / 01 / 2010
Estimated Study Completion Date:
12 / 01 / 2030
Posting Last Modified Date:
05 / 13 / 2022
Date Study Added to neals.org:
01 / 21 / 2013
Minimum Age:
18 Years
Maximum Age:
N/A
Can participants use Riluzole?
Yes
Inclusion Criteria:- U.S. citizens 18 years of age or older
Exclusion Criteria:
-
CDC | Recruiting
Paul Mehta, MD / 770-488-0556 / email hidden; JavaScript is required
Kevin Horton, DrPH, MSPH / 770-488-1555 / email hidden; JavaScript is required
Principal Investigator : Paul Mehta, MD
Atlanta, Georgia
30333
United States